Mayo Clinic, School of Graduate Medical Education, Rochester, MN, United States of America.
Mayo Clinic, Alix School of Medicine, Rochester, MN, United States of America.
Thromb Res. 2024 Jul;239:109028. doi: 10.1016/j.thromres.2024.05.001. Epub 2024 May 10.
Pulmonary vein thrombosis (PVT) is a rare thromboembolic disease with potential high-risk complications related to arterial embolization, but little is known regarding risk factors and outcomes.
To describe the etiology, management, and clinical course of PVT.
Institutional health records were queried (1/1/2001-12/30/2023) to identify patients ≥18 years of age diagnosed with PVT. Thrombosis, bleeding, respiratory failure, and all-cause mortality were analyzed. Suspected tumor thrombus cases were excluded.
72 patients with PVT were identified (median age 62 years, 50 % female), and PVT was overall rare at 3.1 diagnosed cases per year at our institution. PVT primarily affected a single vein (89 %), most commonly the left upper PV (40 %). Of these, 37 % occurred while on therapeutic anticoagulation. The most common risk factors included cancer (55 %) and related surgical lobectomy (21 %). Extrinsic vein compression (17 %) and recent surgery (19 %) were also common; 19 % were deemed idiopathic. Most patients (76 %) were treated with anticoagulation and frequently indefinite duration (80 %). During a median follow-up of 11.7 months (IQR 39.5 months), serial imaging (available for 68 %) revealed PVT resolution in 64 %. Four-year Kaplan-Meier probability of outcome included: left atrial thrombus (21 %), need for mechanical ventilation (14 %), pneumonia (9 %), and ischemic stroke (9 %). The mortality rate was 46 % with median survival 14 months after PVT diagnosis.
PVT is often associated with active malignancy, lobectomy, recent surgery, and extrinsic vein compression; 1 in 5 cases were idiopathic. Notable complications include left atrial thrombus with arterial embolism including stroke. With anticoagulation, most thrombi resolve over time. Mortality rates are high, reflecting the high the prevalence of cancer.
肺静脉血栓形成(PVT)是一种罕见的血栓栓塞性疾病,与动脉栓塞相关的潜在高危并发症,但有关其危险因素和结局的了解甚少。
描述 PVT 的病因、治疗和临床过程。
查询机构健康记录(2001 年 1 月 1 日至 2023 年 12 月 30 日),以确定≥18 岁被诊断为 PVT 的患者。分析血栓形成、出血、呼吸衰竭和全因死亡率。排除疑似肿瘤血栓病例。
共确定 72 例 PVT 患者(中位年龄 62 岁,50%为女性),我院每年 PVT 诊断率为 3.1 例,总体较为罕见。PVT 主要累及单条静脉(89%),最常见于左肺上静脉(40%)。其中 37%发生在接受治疗性抗凝治疗期间。最常见的危险因素包括癌症(55%)和相关的肺叶切除术(21%)。静脉外压迫(17%)和近期手术(19%)也很常见;19%被认为是特发性的。大多数患者(76%)接受抗凝治疗,且经常持续抗凝(80%)。在中位随访 11.7 个月(IQR 39.5 个月)期间,对 68%的患者进行了连续影像学检查,结果显示 64%的 PVT 得到了缓解。4 年 Kaplan-Meier 生存概率包括:左心房血栓(21%)、需要机械通气(14%)、肺炎(9%)和缺血性卒中(9%)。PVT 诊断后 4 年的死亡率为 46%,中位生存时间为 14 个月。
PVT 常与活动性恶性肿瘤、肺叶切除术、近期手术和静脉外压迫相关;1/5 的病例为特发性。值得注意的并发症包括左心房血栓和动脉栓塞,包括卒中。随着抗凝治疗,大多数血栓会随时间消退。死亡率较高,反映了癌症的高患病率。